Why the study?
The study was conducted to investigate the effect of treprostinil on the early postoperative prognosis of patients with severe left heart valvular disease combined with severe pulmonary hypertension.
Does intravenous treprostinil improve early postoperative mean pulmonary artery pressure and recovery times in patients with severe left heart valvular disease and severe pulmonary hypertension undergoing valve replacement?
Cohort (n=55)
No
Does intravenous treprostinil improve early postoperative mean pulmonary artery pressure and recovery times in patients with severe left heart valvular disease and severe pulmonary hypertension undergoing valve replacement?
Absolute Event Rate: 42.5% vs 60.2%
p-value: p=0.028
Intravenous treprostinil safely and effectively reduces pulmonary artery pressure and accelerates early postoperative recovery in patients with severe left heart valvular disease and severe pulmonary hypertension undergoing valve replacement.
Should not yet change practice; hypothesis-generating for treprostinil in severe PH after valve surgery and requires randomized confirmation.
OBJECTIVE: To investigate the effect of treprostinil on the early postoperative prognosis of patients with severe left heart valvular disease combined with severe pulmonary hypertension (PAH). METHODS: A retrospective study including 55 patients with severe left heart valvular disease combined with severe PAH who underwent left heart valve replacement in our hospital between January 2019 and May 2019 was conducted. Patients were divided into two groups (treprostinil group and control group), and the clinical data of patients in the two groups were compared and analyzed. RESULTS: Compared with the preoperative status, the mean postoperative pulmonary artery pressure (mPAP) in both groups was significantly lower. Compared with the control group, the treprostinil group had a significantly lower mPAP. Moreover, the postoperative mechanical ventilation time, intensive care unit (ICU) stay, and hospital stay of the treprostinil group were significantly shorter than those of the control group. There were no serious drug-related side effects in either group. CONCLUSIONS: Treprostinil can improve the early postoperative prognosis of patients with severe left heart valvular disease combined with severe PAH undergoing prosthetic valve replacement.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2020) conducted a cohort in Severe left heart valvular disease combined with severe pulmonary hypertension (n=55). Treprostinil vs. Milrinone was evaluated on Postoperative pulmonary hypertension (mPAP) measured by TTE (p=0.028).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: